BNP Paribas Asset Management
REVB icon

BNP Paribas Asset Management’s Revelation Biosciences REVB Stock Holding History

BNP Paribas Asset Management’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11 Sell
9
-1
-10% -$2 ﹤0.01% 2258
2025
Q4 		$0 Buy
+10
New +$44 ﹤0.01% 2300

Other funds holding REVB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

BNP Paribas Asset Management's REVB Position: Q1 2026 in Review

BNP Paribas Asset Management reduced its Revelation Biosciences (REVB) stake by 10% in Q1 2026, selling an estimated $2 and leaving 9 shares worth $11. The position accounts for ﹤0.01% of the portfolio, ranked #2258.

BNP Paribas Asset Management first reported a position in REVB in Q4 2025 and has held it in 2 quarters since. 12 funds tracked by Wall St. Rank hold REVB as of Q1 2026.

  • BNP Paribas Asset Management held 9 shares of Revelation Biosciences worth $11 as of Q1 2026.
  • BNP Paribas Asset Management sold 1 Revelation Biosciences share in Q1 2026, an estimated $2.
  • Revelation Biosciences made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #2258 holding.
  • BNP Paribas Asset Management first reported a position in Revelation Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.